Fig. 7: CD8+ T cells provide an added layer of metastasis immune surveillance in MSI tumors.
From: Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease
a, Metastatic burden (% tumor area) in the liver (left) or lung (right) of BL/6 mice after tail vein injection of MYC-p53−/− (MSS, blue, n = 9 or 10 mice) or MYC-p53−/−-Msh2−/− (MSI, red, n = 8 or 9 mice) gastric cancer cells. Mice were treated with either an NK1.1-targeting antibody or IgG control. Data are presented as mean ± s.e.m. b, Incidence of lung metastasis after tail vein injection of MSS or MSI gastric cancer cells into immunocompetent (C57BL/6) or immunodeficient (R2G2) mice. Exact numbers of independent mice are indicated on each bar. c, H&E staining of lungs isolated from mice in b. Representative of n = 11 mice (MSI in R2G2) or n = 12 mice (all other conditions) per group. d, Incidence of lung metastasis after tail vein injection of MSS or MSI gastric cancer cells into immunocompetent (C57BL/6) mice that were treated with either CD4- or CD8-targeting antibodies or an IgG control. Exact numbers of independent mice are indicated on each bar. e, H&E images of lungs isolated from mice in d. Exact numbers of independent mice are indicated on each bar. f, Fraction of metastatic samples in the MSK-IMPACT cohort of patients with esophagogastric cancer with either MSS or MSI disease. The exact number of independently analyzed tumors is indicated on each bar. Statistical analyses were ordinary one-way ANOVA (a) and Fisher’s exact test (b,d,f) .
